

Wednesday, May 15, 2019 International Pre-Symposium

The Shifting Landscape of Prescription Drug Abuse:

The Canadian Perspective

### **RADARS International Pre-Symposium**

Housekeeping

- RADARS innovations at the annual meeting
  - RADARS annual report demonstration
  - RADARS NMURx Express topic crowdsourcing



### Agenda

12:00 pm-1:00 pm	Registration
1:00 pm–1:45 pm	Canada and the Global Mosaic: How Does Prescription Drug Abuse Compare?  Janetta L. Iwanicki, MD  Scientific Director of Research and Surveillance, Rocky Mountain Poison & Drug Center,  Denver Health and Hospital Authority
1:45 pm–2:15 pm	Canadian Approach to Prescription Opioid Risk Management Andrew Slot, PhD Manager, Marketed Health Products Directorate, Health Canada
2:15 pm–2:45 pm	Cannabis and Opioids: A Cautionary Tale of Cannabis Policies on the Opioid Epidemic Rosalie Liccardo Pacula, PhD Director, BING Center for Health Economics; Co-Director, Drug Policy Research Center; Senior Economist; Professor, Pardee RAND Graduate School; RAND Corporation
2:45 pm-3:15 pm	Break



### **Agenda**

3:15 pm-4:30 pm	Comparing Canada and the United States: The RADARS® System
	Codeine in Canada – Don't Forget Weak Opioids  Beth Sproule, RPh, BScPhm, PharmD  Centre for Addiction and Mental Health and Leslie Dan Faculty of Pharmacy, University of Toronto
	Emerging Changes in Opioid Diversion in Canada and the United States  Mance E. Buttram, PhD  Associate Director, Center for Applied Research on Substance Use and Health Disparities,  Nova Southeastern University
	Steven P. Kurtz, PhD Professor and Director, Center for Applied Research on Substance Use and Health Disparities, Nova Southeastern University
	Who's Winning? Opioid Abuse Patterns in the United States and Canada Theodore J. Cicero, PhD John P. Feighner Professor of Psychiatry, Department of Psychiatry, Washington University in St. Louis School of Medicine
4:30 pm-5:00 pm	Panel Discussion and Summary

Executive Director, RADARS® System, Denver Health and Hospital Authority

President, Canadian Consumer Product and Pharmaceutical Safety Inc.

Richard C. Dart, MD, PhD (Moderator)





# Canada and the Global Mosaic: How Does Prescription Drug Use Compare?

Janetta L. Iwanicki, MD

Scientific Director of Research and Surveillance


**Rocky Mountain Poison and Drug Center** 

### The Global Mosaic: Can We Compare Apples and Oranges?

- Prescription medications vary widely across countries
  - Prescribing patterns
  - Medication availability
  - Cultural and social trends
- Each country measures the impacts of nonmedical use differently
  - Nationwide surveys
  - Nationwide databases
- How can we transition to comparing apples to apples?




## WHO: Total Opioid Consumption (Morphine Equivalence Mg/Capita), 1980-2015



By: Pain & Policy Studies Group, University of Wisconsin/WHO Collaborating Center, 2018



#### **RADARS Global Mosaic**





# Survey of Non-Medical Use of Rx Drugs (NMURx) Coverage

• UK: 3Q14

• Singapore: 3Q15

• US, Canada: 3Q16

• France, Italy: 2Q17

• Germany, Spain: 4Q17

Methodology optimization projects in 2018





# Survey of Non-Medical Use of Prescription Drugs (NMURx)

- An online, cross-sectional survey that assesses prescription and illicit drug use in the general adult population
- 10,000 30,000 unique individuals twice annually
- Same survey
  - Canada
  - United Kingdom
  - Germany
  - France
  - Spain
  - Italy




#### The Global Mosaic of Nonmedical Use: 10,000 foot view

- Survey of Nonmedical Use of Prescription Drugs
  - Standardized survey in multiple countries
  - Allows direct cross-country comparisons
  - Each country has a "fingerprint" of patterns of nonmedical use
- Prevalence by class of drug
- Gives an initial idea of what the country-by-country trends are




### The Global Mosaic of Nonmedical Use: 10,000 foot view NMURx 2018 Prescription Opioids





### The Global Mosaic of Nonmedical Use: 10,000 foot view NMURx 2018 Prescription Stimulants






### The Global Mosaic of Nonmedical Use: 10,000 foot view NMURx 2018 Sedatives





## The Global Mosaic of Nonmedical Use: 10,000 foot view NMURx 2018 GABA Drugs






### The Global Mosaic of Nonmedical Use: Zooming In

- Can zoom in within NMURx data for more detail:
  - By product
  - By geography
  - By behavior

Focusing on opioid APIs by country




## The Global Mosaic of Nonmedical Use: Zooming In NMURx 2018 Opioid Nonmedical Use by APIs





## The Global Mosaic of Nonmedical Use: Zooming In NMURx 2018 Opioid Abuse by APIs





### The Global Mosaic of Nonmedical Use: Zooming In by Country

 Detailed data within each country provides more clear patterns of use and opportunities for intervention


Canada as a case study in prescription drug misuse beyond the US

- Presentations later today will include:
  - Canadian NMURx data with a focus on codeine
  - Canadian Drug Diversion data
  - Canadian Opioid Dependence Treatment Program data




13TH ANNUAL SCIENTIFIC MEETING

### **Opioid Consumption in Canada**



### **Opioid-Associated Mortality in Canada**



<sup>&</sup>lt;sup>a</sup> British Columbia reports unintentional deaths related to all illicit drugs including, but not limited to, opioids.




<sup>\*</sup>Expected to rise

#### Innovations in Use of Current Data: StreetRx

http://streetrx.com

- Population
  - Any person with access to the internet
- Type of Cases
  - Utilize crowdsourcing methodology
  - Report street price paid for specific prescription drug





### Innovations in Use of Current Data: StreetRx and Crossborder Trafficking

Crowd-sourced real-time data on street prices for diverted drugs


 Able to choose from list of drugs that includes some not currently legal in the US or Canada

Differences in both formulations and APIs available in each country


Confirmatory questions regarding source and location of purchase



### StreetRx Program (www.streetrx.com)



CIENTIFIC MEETING





### **Cross-Border Trafficking**

- 97,914 reports during study timeframe
- Canadian-manufactured prescription oxycodone products was reported 433 times on US website
  - 351 (81%) products acquired in the US
  - 42 (10%) products acquired in Canada
  - 96% were crushable oxycodone
- Canadian website reported 20 hydrocodone and 5 oxymorphone purchases



### **Cross-Border Trafficking**

• 25% cases reported in border states

- Popular destinations also well-represented
  - California, Florida

Implications for policy in both countries

More data needed on relative street prices and trafficking patterns



#### The Global Mosaic of Nonmedical Use: Conclusions

- Survey of Nonmedical Use of Prescription Drugs
  - Standardized survey in multiple countries
  - Allows direct cross-country comparisons
  - Each country has a "fingerprint" of patterns of nonmedical use

- Emerging patterns
  - Opioids and sedatives in Spain
  - Stimulants in UK
  - GABA drugs across countries



#### The Global Mosaic of Nonmedical Use: Conclusions

- Emerging patterns
  - Codeine is ubiquitous
  - Hydromorphone in Canada
  - Tramadol in UK and Spain

- Cross-border trafficking remains an issue
  - Both US drugs in Canada and Canadian drugs in US
  - Implications for policy in both countries



### Agenda

12:00 pm-1:00 pm	Registration
1:00 pm–1:45 pm	Canada and the Global Mosaic: How Does Prescription Drug Abuse Compare?  Janetta L. Iwanicki, MD  Scientific Director of Research and Surveillance, Rocky Mountain Poison & Drug Center,  Denver Health and Hospital Authority
1:45 pm–2:15 pm	Canadian Approach to Prescription Opioid Risk Management Andrew Slot, PhD Manager, Marketed Health Products Directorate, Health Canada
2:15 pm–2:45 pm	Cannabis and Opioids: A Cautionary Tale of Cannabis Policies on the Opioid Epidemic Rosalie Liccardo Pacula, PhD Director, BING Center for Health Economics; Co-Director, Drug Policy Research Center; Senior Economist; Professor, Pardee RAND Graduate School; RAND Corporation
2:45 pm-3:15 pm	Break



### **Agenda**

3:15 pm-4:30 pm	Comparing Canada and the United States: The RADARS® System
	Codeine in Canada – Don't Forget Weak Opioids  Beth Sproule, RPh, BScPhm, PharmD  Centre for Addiction and Mental Health and Leslie Dan Faculty of Pharmacy, University of Toronto
	Emerging Changes in Opioid Diversion in Canada and the United States  Mance E. Buttram, PhD  Associate Director, Center for Applied Research on Substance Use and Health Disparities,  Nova Southeastern University
	Steven P. Kurtz, PhD Professor and Director, Center for Applied Research on Substance Use and Health Disparities, Nova Southeastern University
	Who's Winning? Opioid Abuse Patterns in the United States and Canada Theodore J. Cicero, PhD John P. Feighner Professor of Psychiatry, Department of Psychiatry, Washington University in St. Louis School of Medicine
4:30 pm-5:00 pm	Panel Discussion and Summary

Executive Director, RADARS® System, Denver Health and Hospital Authority

President, Canadian Consumer Product and Pharmaceutical Safety Inc.

Richard C. Dart, MD, PhD (Moderator)



### **RADARS International Pre-Symposium**

Housekeeping

- RADARS innovations at the annual meeting
  - RADARS annual report demonstration
  - RADARS NMURx Express topic crowdsourcing

